ARS Pharmaceuticals, Inc. (SPRY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.65-13.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SPRY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 50.3% |
Growth built into the price is above our model estimate.
The price assumes 131.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
SPRY — earnings miss
Dated 2026-08-13
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless…
Why it matters: Q2 neffy revenue reached $26.2 million, and total U.S. share rose to 5%. More growth would show the focused sales plan is working.
Supportive ifIn the Nov. 9 results, neffy U.S. revenue rises above $26.2 million and total market share rises above 5%.
Worry ifNeffy U.S. revenue falls below $26.2 million or total market share falls below 5%.
Why it matters: ALK handles sales in these markets. Launch progress could add partner revenue beyond U.S. sales, but the company did not give a revenue target.
Supportive ifALK announces a launch in Canada and reports sales of EUR neffy in Europe.
Worry ifALK reports that either launch is delayed. Or, later company results show no collaboration or supply revenue from these markets.
Why it matters: The trial tests nasal epinephrine for acute CSU flares. There is no FDA-approved on-demand treatment for these flares, so the data could shape the program's next step.
Watch forThe interim data meet the trial's stated main measure versus placebo. The company reports the planned Q1 2027 readout.
Also watch forThe interim data fail to meet the trial's stated main measure versus placebo, or the readout moves past Q1 2027.
Why it matters: Management set a second-half cash expense range of $100 million to $110 million. Meeting it supports the stated path to cash flow breakeven by end of 2027.
Supportive ifReported second-half 2026 cash-based SG&A and R&D expenses are $110 million or less. SG&A cash costs are more than 40% below the first half.
Worry ifReported second-half cash-based SG&A and R&D expenses exceed $110 million. Or, SG&A cash costs fall less than 40% from the first half.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$275 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $753 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,971 loss on $10,000 · 79.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: These accounts had 8% share in Q2, versus 5% across the U.S. market. Further gains would support management's focus on high-volume prescribers.
Supportive ifThe next reported share for field-targeted accounts rises above 8%, while total U.S. share stays at or above 5%.
Worry ifField-targeted account share falls below 8%, or total U.S. share falls below 5%.